Mandate

Vinge assisted Industrifonden in connection with the sale of shares in Oncopeptides AB (publ) through an accelerated bookbuilding process

August 17, 2018

In total, 1,2 million shares were placed at a price of SEK 148 per share, corresponding to a total value of approximately SEK 178 million.

Following the transaction, Industrifonden holds approximately 23.67% of the shares in Oncopeptides.
 
Vinge’s team consisted of Dain Hård Nevonen, Rikard Lindahl and Sofie Bjärtun.

Related

Vinge has advised Embracer Group in connection with a EUR 900 million bridge facility agreement entered into with JP Morgan, BNP Paribas, SEB, Société Générale and Swedbank

Vinge has advised Embracer Group AB (publ) (“Embracer”) and its subsidiary group Asmodee in connection with the entry into of a EUR 900,000,000 financing agreement with JP Morgan, BNP Paribas, SEB, Société Générale and Swedbank and concurrent prepayment of existing Embracer indebtedness.
April 22, 2024

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024